A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) targeted therapies are crucial for cancer treatment but face clinical limitations.
• Understanding novel signaling pathways involved in EGFR activation is essential for developing alternative therapeutic strategies.

Purpose of the Study:

• To investigate a novel cross-talk mechanism involving neuraminidase-1 (Neu1), matrix metalloproteinase-9 (MMP-9), and GPCR neuromedin B in EGFR activation.
• To evaluate the therapeutic potential of targeting this pathway, specifically using Tamiflu, for human pancreatic cancer treatment.

Main Methods:

• Investigated the formation of a cell surface complex between Neu1, MMP-9, and EGFR.
• Utilized various inhibitors including Tamiflu, anti-Neu1 antibodies, and MMP inhibitors to assess their effects on Neu1 activity and EGFR phosphorylation.
• Conducted preclinical xenograft studies using human pancreatic cancer cells in mice to evaluate Tamiflu's efficacy in vivo.

Main Results:

• A novel cross-talk between Neu1, MMP-9, and neuromedin B was identified as essential for EGF-induced EGFR activation.
• Tamiflu, anti-Neu1 antibodies, and MMP inhibitors effectively reduced Neu1 activity and EGFR phosphorylation.
• Preclinical studies demonstrated that Tamiflu significantly impeded human pancreatic cancer growth and metastasis, altering key signaling pathways within tumors.

Conclusions:

• The study identifies a novel therapeutic target and strategy for human pancreatic cancer by inhibiting the Neu1-MMP-9-EGFR axis.
• Tamiflu shows promise as an alternative therapeutic agent for pancreatic cancer, warranting further clinical investigation.